Evaluate Efficacy and Safety of XELOX in Potentially Resectable Liver Metastasis From Colorectal Cancer(CRC)

Inclusion Criteria: * Age of 18 and 65 * Histologically confirmed colorectal cancer and two methords of imaging detection confirmed liver metastasis * Potentially curable by resection, as determined by a surgeon with hepatic surgery expertise * No evidence of extrahepatic disease by chest x-ray or CT scan of the chest, abdomen, and pelvis * Patients with adequate hepative, renal and bone marrow function * Signed written informed consent Exclusion Criteria: * Pregnant or nursing patients (fertile patients must use effective contraception) * Other malignancy within the past 5 years except completely resected nonmelanoma skin cancer or carcinoma in situ of the cervix * Preexisting grade 2 or greater peripheral neuropathy * Concurrent uncontrolled illness * Ongoing or active infection * Psychiatric illness or social situation that would preclude study compliance * Less than 6 months since prior adjuvant fluorouracil-based chemotherapy * Prior chemotherapy for liver metastasis * Prior oxaliplatin for colorectal cancer * Prior or concurrent hepatic artery infusion chemotherapy for metastatic disease * Prior or concurrent radiotherapy for metastatic disease * Prior or concurrent radiofrequency ablation for metastatic disease * concurrent treatment with any other anti-cancer therapy.